ZA200005923B - Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives. - Google Patents

Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives.

Info

Publication number
ZA200005923B
ZA200005923B ZA200005923A ZA200005923A ZA200005923B ZA 200005923 B ZA200005923 B ZA 200005923B ZA 200005923 A ZA200005923 A ZA 200005923A ZA 200005923 A ZA200005923 A ZA 200005923A ZA 200005923 B ZA200005923 B ZA 200005923B
Authority
ZA
South Africa
Prior art keywords
antibacterial agents
enhancement
oxazolidinone antibacterial
arginine derivatives
agents activity
Prior art date
Application number
ZA200005923A
Other languages
English (en)
Inventor
Michael John Bohanon
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ZA200005923B publication Critical patent/ZA200005923B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200005923A 1998-05-18 2000-10-23 Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives. ZA200005923B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8116498A 1998-05-18 1998-05-18

Publications (1)

Publication Number Publication Date
ZA200005923B true ZA200005923B (en) 2001-10-23

Family

ID=22162494

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200005923A ZA200005923B (en) 1998-05-18 2000-10-23 Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives.

Country Status (25)

Country Link
US (1) US6251869B1 (fr)
EP (1) EP1077718B1 (fr)
JP (1) JP2002515450A (fr)
KR (1) KR20010043695A (fr)
CN (1) CN1170584C (fr)
AT (1) ATE222115T1 (fr)
AU (1) AU746606B2 (fr)
BR (1) BR9910443A (fr)
CA (1) CA2327100A1 (fr)
CZ (1) CZ291945B6 (fr)
DE (1) DE69902526T2 (fr)
DK (1) DK1077718T3 (fr)
EA (1) EA003458B1 (fr)
ES (1) ES2182521T3 (fr)
HK (1) HK1036222A1 (fr)
HU (1) HUP0101958A3 (fr)
IL (1) IL139437A0 (fr)
NO (1) NO20005813L (fr)
NZ (1) NZ508256A (fr)
PL (1) PL344049A1 (fr)
PT (1) PT1077718E (fr)
SK (1) SK283038B6 (fr)
TR (1) TR200003384T2 (fr)
WO (1) WO1999059616A1 (fr)
ZA (1) ZA200005923B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794974B1 (fr) * 1999-06-16 2001-08-17 Exsymol Sa Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US20050255538A1 (en) * 2002-03-15 2005-11-17 Buxser Stephen E Methods for screening for AcrAB efflux pump inhibitors
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
WO2006002896A1 (fr) * 2004-06-30 2006-01-12 Novartis Ag Methode servant a traiter des infections bacteriennes a gram negatif au moyen d'un inhibiteur de pdf tel que lbm 415 associe a un inhibiteur de pompe d'ecoulement afin d'augmenter la susceptibilite de l'inhibiteur de pdf
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (fr) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention et traitement de troubles thromboemboliques
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
SG166126A1 (en) 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
PL3010511T3 (pl) 2014-09-12 2018-07-31 Antibiotx A/S Przeciwbakteryjne zastosowanie halogenowanych salicylanilidów
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
WO2020176067A1 (fr) 2019-02-25 2020-09-03 Rhode Island Hospital Procédés de traitement de maladies ou d'infections provoquées par ou associées à h. pylori en utilisant un salicylanilide halogéné
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989832A (en) * 1995-04-21 1999-11-23 Microcide Pharmaceuticals, Inc. Method for screening for non-tetracycline efflux pump inhibitors
WO1999002525A1 (fr) * 1997-07-11 1999-01-21 Pharmacia & Upjohn Company Agents antibacteriens de type phenyloxazolidinones de thiadiazolyle et d'oxadiazolyle
US6068972A (en) * 1997-10-03 2000-05-30 Trustees Of Tufts College Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents
US6790856B2 (en) * 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments

Also Published As

Publication number Publication date
NO20005813D0 (no) 2000-11-17
JP2002515450A (ja) 2002-05-28
CA2327100A1 (fr) 1999-11-25
WO1999059616A1 (fr) 1999-11-25
HK1036222A1 (en) 2001-12-28
EP1077718A1 (fr) 2001-02-28
DK1077718T3 (da) 2002-11-11
HUP0101958A3 (en) 2003-07-28
CN1170584C (zh) 2004-10-13
PL344049A1 (en) 2001-09-24
DE69902526D1 (de) 2002-09-19
EA003458B1 (ru) 2003-06-26
EA200001197A1 (ru) 2001-04-23
KR20010043695A (ko) 2001-05-25
CZ291945B6 (cs) 2003-06-18
CN1297355A (zh) 2001-05-30
IL139437A0 (en) 2001-11-25
SK16252000A3 (sk) 2001-06-11
AU3860199A (en) 1999-12-06
NO20005813L (no) 2000-11-17
CZ20004259A3 (en) 2001-05-16
PT1077718E (pt) 2002-12-31
AU746606B2 (en) 2002-05-02
ES2182521T3 (es) 2003-03-01
DE69902526T2 (de) 2003-04-03
EP1077718B1 (fr) 2002-08-14
NZ508256A (en) 2003-08-29
HUP0101958A2 (hu) 2001-10-28
TR200003384T2 (tr) 2001-03-21
ATE222115T1 (de) 2002-08-15
SK283038B6 (sk) 2003-02-04
BR9910443A (pt) 2001-01-02
US6251869B1 (en) 2001-06-26

Similar Documents

Publication Publication Date Title
HK1036222A1 (en) Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives.
NO996269L (no) Kinolin-indol antimikrobielle midler, samt anvendelse og blandinger derav
FI963232A (fi) Antimikrobisena aineena käytettävä hapotettu nitriitti
NO20042271L (no) Formuleringer som inneholder en cefalosporinforbindelse og deres anvendelse for behandling av bakterielle infeksjoner i katter og hunder
DE69831506D1 (en) 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
AP2003002824A0 (en) Gyrase inhibitors and uses thereof
EP1037650A4 (fr) Procedes et compositions pour le traitement et la prevention d'infections a staphylococcus aureus
DE60042401D1 (de) Fab-i inhibitoren
MX9703634A (es) Derivados de dibencimidazol antibacterianos.
DE60318826D1 (de) Alkoxypyridinderivate
WO2001091796A8 (fr) Methodes, composes et compositions permettant de traiter la goutte
DE69615155D1 (de) Basische oxazolinamid-derivate von ge2270 und ge2270-änlichen antibiotika
DE69600244D1 (de) Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
IL140768A0 (en) Chemotaxis-inhibiting protein of staphylococcus (chips) and its use
EA200000697A1 (ru) ПРОИЗВОДНЫЕ БЕНЗО[C]ХИНОЛИЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5α-РЕДУКТАЗ
AU2003259159A1 (en) N-aryl-2-oxazolidinones and their derivatives
BRPI0411537A (pt) derivados de lincomicina que possuem atividade antibacteriana
EA200501830A1 (ru) Новые производные линкомицина, обладающие антимикробной активностью